Invicro, LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, today announced the hiring of Mr. George Abe, as Senior Vice President of Pathology.
Backed by more than 25 years of technology and life science business experience, Mr. Abe will lead and expand Invicro’s global pathology services. Under Konica Minolta Inc.’s (Konica Minolta) recent acquisition and with the Ambry Genetics partnership, Invicro will now have a full-suite of precision medicine capabilities that will offer customers advanced scientific insights into disease diagnosis and targeted therapy development.
“We are very excited to have George join the Invicro team,” said Dr. Jack Hoppin, CEO and Co-Founder of Invicro. “Throughout his career, George has demonstrated entrepreneurial leadership focused on solving customer problems while building strong teams and delivering financial value. Along with his background in leading life science imaging organizations, George is ideally suited to help lead our efforts in providing solutions and services to enable precision medicine. He will play a key role in building our pathology business to scale with value-added imaging solutions and services.”
Prior to joining Invicro, Mr. Abe was President and CEO of Cubresa, a molecular imaging company, since 2015. From 2011 to 2014, he was President of Emerald Biosystems and Biostructures, a structural biology technology provider and contract research organization. Prior to that, from 2002 to 2010, Mr. Abe was President and CEO of quantitative tissue imaging and digital pathology pioneer, Cambridge Research and Instrumentation (CRi), now part of PerkinElmer. He has also served on various public, private, and not for profit boards.
“I have known Jack and the Invicro team for some time. They are truly world class innovators, with a reputation in the market for deep scientific understanding blended with unwavering customer focus,” said Mr. Abe. “With the capabilities and resources of Konica Minolta and our partner organization Ambry Genetics, we are extremely well positioned to provide integrated multi-modal scientific services to our customers. Konica Minolta’s High Sensitivity Tissue Testing (HSTT) technology will change the way quantitative immunohistochemistry is performed. Further, the bio-informatics expertise and resources that the combined businesses have assembled are unparalleled. I look forward to leading the team that is expanding the company’s translational imaging offerings into pathology.”